Return to homepagePandemic Pact

Repurposing of FDA-approved drugs as novel therapeutics for COVID-19

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 170659

Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $340,513.38

  • Funder

    Canadian Institutes of Health Research (CIHR)

  • Principal Investigator

    Pending

  • Research Location

    Canada

  • Lead Research Institution

    CIUSSS de Centre-Ouest-de-l'Ile-de-Montréal-Jewish General

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Currently, there is no vaccine or effective therapeutics for COVID-19, which is caused by 2019-nCoV (now officially referred to as SARS-CoV-2). Tens of thousands of people get infected by SARS-CoV-2 and substantial percentage of them showed severe symptoms. Dr Wu's team proposed to rapidly screen database of FDA-approved drugs by computationally approaches and further evaluate the top-ranking candidates by an array of experimental assays. This project could rapidly lead to drug candidates for COVID-19.